Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $270

Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $260 to $270.